BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 28643285)

  • 1. Skin Manifestations of Inflammatory Bowel Disease.
    Greuter T; Navarini A; Vavricka SR
    Clin Rev Allergy Immunol; 2017 Dec; 53(3):413-427. PubMed ID: 28643285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.
    He R; Zhao S; Cui M; Chen Y; Ma J; Li J; Wang X
    Front Immunol; 2023; 14():1234535. PubMed ID: 37954590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
    J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Hanzel J; Ma C; Casteele NV; Khanna R; Jairath V; Feagan BG
    Drugs; 2021 Feb; 81(3):333-347. PubMed ID: 33400241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.
    King D; Chandan JS; Thomas T; Nirantharakumar K; Reulen RC; Adderley NJ; Trudgill N
    Inflamm Bowel Dis; 2021 Oct; 27(11):1731-1739. PubMed ID: 34669933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
    Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
    Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.
    Barrie A; Regueiro M
    Inflamm Bowel Dis; 2007 Nov; 13(11):1424-9. PubMed ID: 17567879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.
    Rogler G; Singh A; Kavanaugh A; Rubin DT
    Gastroenterology; 2021 Oct; 161(4):1118-1132. PubMed ID: 34358489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-related and drug-induced skin manifestations in inflammatory bowel disease.
    Hindryckx P; Novak G; Costanzo A; Danese S
    Expert Rev Gastroenterol Hepatol; 2017 Mar; 11(3):203-214. PubMed ID: 28095714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis.
    Greuter T; Vavricka SR
    Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):307-317. PubMed ID: 30791773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.
    Vavricka SR; Rogler G; Gantenbein C; Spoerri M; Prinz Vavricka M; Navarini AA; French LE; Safroneeva E; Fournier N; Straumann A; Froehlich F; Fried M; Michetti P; Seibold F; Lakatos PL; Peyrin-Biroulet L; Schoepfer AM
    Inflamm Bowel Dis; 2015 Aug; 21(8):1794-800. PubMed ID: 26020601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease.
    Siemanowski B; Regueiro M
    Curr Treat Options Gastroenterol; 2007 Jun; 10(3):178-84. PubMed ID: 17547856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
    Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.
    Vavricka SR; Gubler M; Gantenbein C; Spoerri M; Froehlich F; Seibold F; Protic M; Michetti P; Straumann A; Fournier N; Juillerat P; Biedermann L; Zeitz J; Misselwitz B; Scharl M; Heinrich H; Manser CN; Safroneeva E; Raja Ali RA; Rogler G; Schoepfer AM; Greuter T;
    Inflamm Bowel Dis; 2017 Jul; 23(7):1174-1181. PubMed ID: 28452862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cutaneous and mucosal manifestations of inflammatory bowel diseases].
    Károlyi Z; Erós N; Ujszászy L; Nagy G
    Orv Hetil; 2000 Jun; 141(25):1391-5. PubMed ID: 10934882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.
    Karmiris K; Avgerinos A; Tavernaraki A; Zeglinas C; Karatzas P; Koukouratos T; Oikonomou KA; Kostas A; Zampeli E; Papadopoulos V; Theodoropoulou A; Viazis N; Polymeros D; Michopoulos S; Bamias G; Kapsoritakis A; Karamanolis DG; Mantzaris GJ; Tzathas C; Koutroubakis IE
    J Crohns Colitis; 2016 Apr; 10(4):429-36. PubMed ID: 26721936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
    Juliao-Baños F; Arrubla M; Osorio L; Camargo J; Londoño J; Cáceres C; Carvajal J; Mosquera-Klinger G; Donado J
    Gastroenterol Hepatol; 2021; 44(6):398-404. PubMed ID: 33172691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Peyrin-Biroulet L; Van Assche G; Gómez-Ulloa D; García-Álvarez L; Lara N; Black CM; Kachroo S
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):25-36.e27. PubMed ID: 27392760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.